Compare AbCellera Biologics Inc (ABCL) vs CarMax, Inc (KMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs CarMax, Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while CarMax, Inc trades at $50.67 (market cap $7.24B). The key difference: CarMax, Inc is far larger — about 3.1× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | KMX | |
|---|---|---|
Market Cap | $2.35B | $7.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $68.38 |
52-Week Low | $2.78 | $30.88 |
Enterprise Value | $1.99B | $25.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CarMax (KMX) trades at $51.05, up 0.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 earnings that beat expectations, with revenue growth and cost control supporting a net income margin of 0.84%. Recent news highlights insider buying and a four-pillar turnaround strategy under new CEO Keith Barr, though margins remain under pressure.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating and $48.91 price target below current levels, but improving cash flow and strategic initiatives offer potential upside. Key risks include persistent margin compression, high debt levels, and execution challenges in a competitive used car market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
